August 13-15, 2012
Day 1 | Day 2 | Day 3 | Download Brochure
Vaccine leaders from around the world will once again come together to discuss critical issues surrounding the development of effective – and affordable – vaccines at the Seventh Annual Novel Vaccines meeting. Day One will explore innovative approaches to conquering infectious diseases including Hepatitis, Dengue Fever and Influenza. Day Two will be devoted to “the Big 3” – HIV, Malaria and Tuberculosis – and the highlighted Plenary Session on Day Three will explore predicting immune response through emerging technologies such as Systems Biology approaches. The Novel Vaccines meeting examines the successful vaccine achievements that respond to the most pernicious diseases threatening humankind. This meeting not only provides a snapshot of where vaccine innovation stands today, but also gives vaccine professionals the opportunity to network, establish collaborations, and learn from leaders in the field.
MONDAY, AUGUST 13
12:00 – 1:30pm Main Conference Registration
1:30 Chairperson’s Opening Remarks
Rhea N. Coler, Ph.D., Vice President, Pre-Clinical Biology, Infectious Disease Research Institute (IDRI)
» Opening Keynote Presentation:
1:40 Status of Hepatitis C Virus (HCV) Vaccines
Michael Houghton, Ph.D., Canada Excellence in Research Chair and Professor, Medical Microbiology & Immunology, University of Alberta - Biography
We can be optimistic about HCV vaccine development based on 1) the demonstration of significant natural immunity in the chimpanzee challenge model and in man, 2) the identification of cellular and humoral correlates of immunity, 3) the demonstration of vaccine efficacy in the chimpanzee challenge model & 4) the recent demonstration of a vaccine able to elicit broadly cross-neutralising antibodies against all major, global genotypes. Current vaccine candidates in clinical development elicit either broad, cross-reactive cellular immune responses or broad, cross-neutralizing antibody responses but combining both is likely to result in at least a partially effective vaccine against this highly heterogeneous virus that is estimated to infect many hundreds of thousands each year around the globe.
2:20 Development of a Prophylactic Vaccine for Hepatitis C Virus Using a Novel E2 Core Domain
Heidi Drummer, Ph.D., Lab Head, Viral Fusion Laboratory, Burnet Institute- Biography
Candidate HCV vaccines have shown limited efficacy in clinical trials. Neutralizing antibodies (NAbs) are a key component of all licensed vaccines. In HCV infection, NAbs are primarily directed to the major surface glycoprotein E2 and have been correlated with viral clearance. However, most HCV specific NAbs are directed to the hypervariable region 1 (HVR1), which are type-specific as the name suggests. By contrast, NAbs directed to the HCV receptor (CD81) binding site show the capacity to mediate broad neutralization, but these antibodies are rarely produced in the presence of the immunodominant HVR1. We have investigated how different oligomeric forms of Δ123 E2 (monomer, dimer and higher order forms) induce different levels of neutralizing antibodies.
2:50 H1N1 Universal Influenza Vaccine
Mark L. Bagarazzi, M.D., Chief Medical Officer, Inovio Pharmaceuticals Corp.
3:20 Refreshment Break
3:45 The sanofi pasteur Tetravalent Dengue Vaccine: An Update
Dany De Grave, Director, Strategic Alignment & Expertise, Product Conception & Development (PCD), sanofi pasteur - Biography
Dengue fever is a mosquito-borne disease caused by four types of dengue viruses (type 1 to 4). The disease is a potential threat for almost half of the world’s population. The sanofi pasteur tetravalent dengue vaccine candidate is composed of four recombinant, live, attenuated chimeric viruses (CYD-1–4), based on a yellow fever virus (YFV17D) backbone, and is in final clinical Phase III and manufacturing scale-up stages. This talk will provide the results of an extensive characterization program and an update on recent vaccine data. Assuming positive results of the first on-going efficacy trial in 4000 Thai vaccinees (4-11 yrs old) by Q42012, this dengue vaccine might now be expected to be available within 3 years.
4:15 A Single Subcutaneous Dose of TetraVax-DV, a Recombinant Live Attenuated Tetravalent Dengue Vaccine, is Highly Immunogenic in Flavivirus-Naïve Adults
Anna Durbin, M.D., Associate Professor, Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health - Biography
Over the past 11 years, the NIH has tested 8 monovalent vaccines in 15 Phase I clinical trials to identify DENV-1, DENV-2, DENV-3, and DENV-4 candidate vaccine viruses that are safe and maintain the optimal infectivity and immunogenicity profiles for inclusion in a tetravalent formulation. Six monovalent DENV candidate vaccines were evaluated in five different tetravalent admixtures in healthy adult flavivirus-naïve subjects to identify those admixtures with the most favorable safety and immunogenicity profiles. Safety, infectivity, and immunogenicity data of the five admixtures following administration of a single subcutaneous dose will be presented. Preliminary data from a second dose administered 6 months after the first dose will also be presented. Factors contributing to the immunogenicity profiles of the different admixtures will be discussed.
4:45 Combinatorial Antibody-Based Immunotherapy: Learning from Current Success
Christopher Nicodemus, Ph.D., Senior Advisor, Chief Executive, Quest Pharmatech - Biography
The success of ipilimumab and sipuleucel T confirm that mobilized immunity can effectively treat cancer. Both approaches modulate immune counter-regulatory pathways. We have studied the interactions of cytotoxics, anti-inflammatories, antigen specific antibodies and other adjuvants and found a profound relationship between dose and schedule of these factors and the quality of the induced immune response. Quest Pharmatech (Edmonton, Alberta) has initiated a phase II clinical trial program to confirm the clinical relevance of these observations and provide the basis for a definitive combinatorial immunotherapy phase III clinical trial program with oregovomab and additional tumor antigen specific antibodies to be administered as combinatorial therapies. These observations should apply to other traditional cancer vaccines that have here-to-for failed to prove safety and efficacy.
5:15 Welcome Reception with Poster and Exhibit Viewing
6:30 Close of Day
Day 1 | Day 2 | Day 3 | Download Brochure